Wissenschaftliche Projekte, Studien, Veröffentlichungen, Fortbildungs-Veranstaltungen und Ausbildung gehören neben unserer Kerntätigkeit zu den Aufgaben eines Lehrkrankenhauses.

Hier finden Sie weitere Informationen zu unseren Veröffentlichungen:

Ferdinandus J, Barbato F, Chodyla M, Fendler WP, Kessler L, Pomykala KL, Metzenmacher M, Krefting F, Hager T, Umutlu L, Herrmann K, Christoph DC (2020): Volumetric PET response assessment outperforms conventional criteria in patients receiving high-dose pembrolizumab for malignant mesothelioma. J Nucl Med., in Druck.

Jia Z, Wang Y, Cao L, Wang Y, Song Y, Yang X, Bing Z, Cao Z, Liu P, Zhang S, Chen Z, Huang M, Yu Y, Han-Zhang H, Song J, Christoph DC, Passaro A, Gridelli C, Hishida T, Liang N, Li S (2020): First-line treatment selection with organoids of an EGFRm + TP53m stage IA1 patient with early metastatic recurrence after radical surgery and follow-up. J Thorac Dis. 12(7):3764-3773.

Staehler M, Stöckle M, Christoph DC, Stenzl A, Potthoff K, Grimm MO, Klein D, Harde J, Brüning F, Goebell PJ, Augustin M, Roos F, Benz-Rüd I, Marschner N, Grünwald V (2020): Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: Final results of the MARC-2 trial. Int J Cancer, in Druck.

Faehling M, Schumann C, Christopoulos P, Hoffknecht P, Alt J, Horn M, Eisenmann S, Schlenska-Lange A, Schütt P, Steger F, Brückl WM, Christoph DC (2020): Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP). Lung Cancer 150:114-122.

Faehling M, Schumann C, Christopoulos P, Hoffknecht P, Alt J, Horn M, Eisenmann S, Schlenska-Lange A, Schütt P, Steger F, Brückl WM, Christoph DC (2020). Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP. Data Brief 34:106556.

Fehr M, Hawle H, Hayoz S, …… Stahl M, Ruhstaller T, for the Swiss Group for Clinical Cancer Research (SAKK) the German Esophageal Cancer Study Group, the Austrian Arbeitsgemeinschaft Medikamenöse Tumortherapie (AGMT) and the Federation de Cancerologie Digestive (FFCD) / Federation de Recherche en Chirurgie (FRENCH) (2020) High thrombembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective, randomised intergroup phase III trial SAKK 75/08. BMC Cancer 20:166-174.

Lorenzen S, Knorrenschild J, Pauligk C, Hegewisch-Becker S, Seraphin J, Thuss-Patience P, Knopp H, Dechow T, Vogel A, Luley K, Pink D, Stahl M, Kullmann F, Hebart H, Siveke J, Egger M, Homann N, Probst S, Goetze T, Al-Batran S. (2020) Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Int J Cancer 147:2493-2502.Folprecht G, Trautmann K, Stein A, Huebner G, Stahl M, Kasper S, Kretzmar A, Köhne CH, ….. Krämer A, Arbeitsgemeinschaft Internistische Onkologie – CUP Group (2020) Adding Cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the phase II AIO trial PACET-CUP. Brit J Cancer, in Druck.

Girard N, Fietkau R, Garassino M, Garrido P, Field JK, Peters S, Smit HJM, Pérol M, Merle P, Sibille A, Markman B, Bouchaab H, Moskovitz M, Schumann C, Gregorc V, Klein AB, Diaz Perez I, Sawyer W, Licour M, Christoph D (2020): Characteristics of the first 615 patients enrolled in Pacific R: A study of the first real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. Ann Oncol. 31 (S4), P1242. Posterpräsentation auf der Jahrestagung der European Society of Medical Oncology 2020.

 

Faehling M, Schumann C, Christopoulos P, Hoffknecht P, Alt J, Horn M, Eisenmann S, Schlenska -Lange A, Aries SP, Sackmann S, Schuett P, Steger F, Christoph D (2020): Durvalumab after definitive radiochemotherapy (RCT) in locally advanced unresectable NSCLC: Real-world data on survival and safety from the German expanded access program (EAP) Ann Oncol. 31 (S4), P1244.

Posterpräsentation auf der Jahrestagung der European Society of Medical Oncology 2020.

 

Christoph DC, Barbato F, Chodyla M-K, Fendler WP, Kessler L, Pomykala KL, Metzenmacher M, Krefting F, Hager T, Herrmann K, Ferdinandus J (2020): Volumetric PET response assessment outperforms conventional criteria in patients receiving high-dose pembrolizumab for malignant mesothelioma. Ann Oncol. 31 (S4), MO1896. Kurzvortrag auf der Jahrestagung der European Society of Medical Oncology 2020.

 

Christoph DC, Rizzo F, Kambartel K-O, Winke S, Panse J, Abdulla DS, Scheffler M, Azeh IT, Hoiczyk M, Turki A, Metzenmacher M (202):  Docetaxel/nindetanib as efficient treatment option after failure of immune checkpoint inhibition: Real-world evidence. Ann Oncol. 31 (S4), P1374. Posterpräsentation auf der Jahrestagung der European Society of Medical Oncology 2020.

 

Shah R, Klotz LV, Feißt M, Schneider M, Kriegsmann M, Ried M, Wesseler C, Christoph DC, de Wit M, Jürgens J, Kopp H-G, Wehler T, Reck M, Sackmann S, Waller C, Reinmuth N,  Bischoff H, Winter H , Eichhorn M, Thomas M (2020):  NICITA: Nivolumab with chemotherapy in pleural mesothelioma after surgery. Ann Oncol. 31 (S4), TiP1912. Posterpräsentation auf der Jahrestagung der European Society of Medical Oncology 2020.

Eine Auflistung unserer aktuell durchgeführten Studien finden Sie hier:

Studiennummer: Skycraper-07 (YO42137)
Studientitel: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNRESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA WHOSE CANCERS HAVE NOT PROGRESSED FOLLOWING DEFINITIVE CONCURRENT CHEMORADIOTHERAPY
Verantwortlicher Arzt: Prof. Dr. Michael Stahl
Status: geöffnet

Studiennummer: INNOVATION (EORTC GITCG 1203)
Studientitel: INtegratioN of trastuzumab, with or without pertuzumab, into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL.
Verantwortlicher Arzt: Prof. Dr. Michael Stahl
Status: geöffnet

Studiennummer: Renaissance (ReCure-FLOT 5-RAVE)
Studientitel: Chemotherapy alone vs. Chemotherapy followed by surgical resection for limited metastatic adenocarcinoma of the stomach or esphagogastric junction-a randomized multicenter phase III trial of the AIO in cooperation with CAO-V/CAOGI
Verantwortlicher Arzt: Prof. Dr. Michael Stahl
Status: geöffnet

Studiennummer: MK3475-585
Studientitel: A Phase III, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) (SCH-900475) plus Chemotherapy (XP or FP) vs. Placebo plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Gastric and Gastroesophageal Junction Adenocarcinoma
Verantwortlicher Arzt: Prof. Dr. Michael Stahl
Status: geöffnet

Studiennummer: Ramiris II/III
Studientitel: Ramucirumab plus Irinotecan / Leucovorin / 5-FU versus Ramucirumab plus Paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy
Verantwortlicher Arzt: Prof. Dr. Michael Stahl
Status: geöffnet

Studiennummer: RACE
Studientitel: Neoadjuvant Radiochemotherapy versus Chemotherapy for Patients with Locally Advanced, Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ)
Verantwortlicher Arzt: Prof. Dr. Michael Stahl
Status: geöffnet

Studiennummer: ACO/ARO/AIO 18.1
Studientitel: Short-course radiotherapy versus chemoradiotherapy, followed by consolidation chemotherapy, and selective organ preservation for MRI-defined intermediate and high-risk rectal cancer patients.
A randomized phase III trial of the German Rectal Cancer Study Group
Verantwortlicher Arzt: Dr. Christian Müller
Status: geöffnet

Studiennummer: ACO/ARO/AIO 18.2
Studientitel: Preoperative FOLFOX versus postoperative risk-adapted chemotherapy in patients with locally advanced rectal cancer and low risk for local failure:
A randomized phase III trial of the German Rectal Cancer Study Group
Verantwortlicher Arzt: Prof. Dr. Michael Stahl
Status: geöffnet

Studiennummer: MoLiMoR
Studientitel: Modulation of the FOLFIRI-based standard 1st-line therapy with cetuximab, controlled by monitoring the RAS mutation load by liquid biopsy in RASmutated mCRC patients.
A randomized phase II study with FOLFIRI-based 1stline therapy with or without intermittent cetuximab
Verantwortlicher Arzt: Prof. Dr. Michael Stahl
Status: geöffnet

Studiennummer: Elderly (AIO-KRK-0117)
Studientitel: Aflibercept and 5-FU vs. FOLFOX as 1st line treatment for elderly or frail elderly patients with metastatic colorectal cancer
Verantwortlicher Arzt: Prof. Dr. Michael Stahl
Status: geöffnet

Studiennummer: Fire 4.5 (AIO-KRK-0116)
Studientitel: Randomisierte Studie zur Untersuchung von FOLFOXIRI plus Cetuximab oder FOLFOXIRI plus Bevacizumab als Erstlinientherapie des BRAF mutierten metastasiertem kolorektalen Karzinoms.
Verantwortlicher Arzt: Dr. Christian Müller
Status: geöffnet

Studiennummer: Cirulate (AIO-KRK-0217)
Studientitel: Circulating tumor DNA based decision for adjuvant treatment in colon cancer stage II evaluation.
Verantwortlicher Arzt: Dr. Christian Müller
Status: geöffnet

Studiennummer: CheckMate (CA209-274)
Studientitel: A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma (CheckMate 274: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 274)
Verantwortlicher Arzt: Prof. Dr. Susanne Krege
Status: geöffnet

Studiennummer: FOOTPATH
Studientitel: A multicenter randomized phase II study to determine the optimal first-line chemotherapy regimen in patients with metastatic pancreatic cancer
Verantwortlicher Arzt: Prof. Dr. Michael Stahl
Status: geöffnet

Studiennummer: DEMAND
Studientitel: A randomized, 2-arm non-comparative phase II study on the efficacy of atezolizumab and Roche bevacizumab (Atezo/Bev) followed by ondemand selective TACE (sdTACE) upon detection of disease progression or of initial synchronous treatment with TACE and Atezo/Bev on 24-months survival rate in the treatment of unresectable hepatocellular carcinoma patients
Verantwortlicher Arzt: Dr. Stefan Pluntke
Status: geöffnet

Studiennummer: IMMUWHY ( AIO-HEP-0119/ass)
Studientitel: A phase II study of immunotherapy with durvalumab (MEDI4736) or durvalumab and tremelimumab, both combined with Y-90 SIRT therapy in patients with advanced stage intrahepatic biliary tract cancer (BTC) scheduled to receive Y-90 SIRT therapy as standard of care

Verantwortlicher Arzt: Dr. Stefan Pluntke
Status: geöffnet

Studiennummer: CA2099DW (CheckMate 9DW)
Studientitel: A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma

Verantwortlicher Arzt: Dr. Stefan Pluntke
Status: geöffnet

Studiennummer: CaboRISE (AIO-HEP-0320)
Studientitel: A phase II study evaluating reduced starting dose and dose escalation of cabozantinib as second-line therapy for advanced HCC in patients with compensated liver cirrhosis
Verantwortlicher Arzt: Dr. Stefan Pluntke
Status: geöffnet

Studiennummer: Dolpin
Studientitel: A Phase II randomized Study to evaluate the efficacy and safety of Cisplatin / Etoposide and concomitant radiotherapy combined with Durvalumab followed by Maintenance Therapy with Durvalumab versus Cisplatin / Etoposide and concomitant Radiotherapy in Patients with limited disease Small Cell Lung Cancer
Verantwortlicher Arzt: Dr. Daniel Christoph
Status: geöffnet

Studiennummer: MK7339-008
Studientitel: A Phase 3 Study of Pembrolizumab in Combination with Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Verantwortlicher Arzt: Dr. Daniel Christoph
Status: geöffnet

Studiennummer: MK7339-006
Studientitel: A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer
Verantwortlicher Arzt: Dr. Daniel Christoph
Status: geöffnet

Studiennummer: NICITA
Studientitel: Nivolumab with chemotherapy in pleural mesothelioma after surgery
Verantwortlicher Arzt: Dr. Daniel Christoph
Status: geöffnet

Studiennummer: CONTACT-01 (GO41892)
Studientitel: A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF ATEZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS DOCETAXEL MONOTHERAPY IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER PREVIOUSLY TREATED WITH AN ANTI-PD-L1/PD-1 ANTIBODY AND PLATINUM-CONTAINING CHEMOTHERAPY
Verantwortlicher Arzt: Dr. Daniel Christoph
Status: geöffnet

Studiennummer: CheckMate 73L (CA209-73L)
Studientitel: A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer
(CheckMate 73L: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 73L)
Verantwortlicher Arzt: Dr. Daniel Christoph
Status: geöffnet

Studiennummer: DEMAND
Studientitel: A randomized, 2-arm non-comparative phase II study on the efficacy of atezolizumab and Roche bevacizumab (Atezo/Bev) followed by ondemand selective TACE (sdTACE) upon detection of disease progression or of initial synchronous treatment with TACE and Atezo/Bev on 24-months survival rate in the treatment of unresectable hepatocellular carcinoma patients
Verantwortlicher Arzt: Dr. Stefan Pluntke
Status: geöffnet

Studiennummer: IMMUWHY ( AIO-HEP-0119/ass)
Studientitel: A phase II study of immunotherapy with durvalumab (MEDI4736) or durvalumab and tremelimumab, both combined with Y-90 SIRT therapy in patients with advanced stage intrahepatic biliary tract cancer (BTC) scheduled to receive Y-90 SIRT therapy as standard of care

Verantwortlicher Arzt: Dr. Stefan Pluntke
Status: geöffnet

Studiennummer: Cupisco (MX39795)
Studientitel: A PHASE II, RANDOMIZED, ACTIVE-CONTROLLED, MULTI-CENTER STUDY COMPARING THE EFFICACY AND SAFETY OF TARGETED THERAPY OR CANCER IMMUNOTHERAPY GUIDED BY GENOMIC PROFILING VERSUS PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH CANCER OF UNKNOWN PRIMARY SITE WHO HAVE RECEIVED THREE CYCLES OF PLATINUM DOUBLET CHEMOTHERAPY
Verantwortlicher Arzt: Prof. Dr. Michael Stahl
Status: geöffnet

Studiennummer: GEON 1
Studientitel: Einfluss der Daten eines geriatrischen Assessments auf Toxizität, Überleben und Lebensqualität betroffener Patienten
Verantwortlicher Arzt: Dr. Sebastian Ertl
Status: geöffnet

Studiennummer: SCREBEL
Studientitel: Niederschwelliges Screening versus multidimensionals Assment von Symptomen und psychosozialen Belastungen bei Krebspatienten ab dem Zeitpunkt der Inkurabilität.
Verantwortlicher Arzt: Dr. Susanne Stevens
Status: geöffnet